Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (1884)	8/24/1999 9:43:00 PM
From: Marshall Teitelbaum	Respond to of 2205

Hey Rick and all....a few old names returning....hello everyone. Interesting release by ORTC today: biz.yahoo.com 32 people for the study only. Also, of interest, is the Bordeaux European tissue engineering meeting this week. ORG has all of a sudden taken off the last two days, leading me to believe that something considered good news might be coming out. However, yesterday the whole skin sector had a good day(ie ATIS, ORG, ORTC, etc.). Regarding the question of rejection, I think we had gone over this area in a lot of detail at least a year or so ago, so it might be worth going back to read. However, there was no obvious source of immune reaction with the foreskin cells used as the basis of the engineered skin......antigenicity being a factor. Regards, Marshall